 |
| Global Anti-Suicide Drugs Market |
Suicidal
thoughts can be aroused due to various underlying factors such as
financial burden, social issues or drug side effects. Treatment for
suicidal thoughts includes psychotherapy, medications, addiction
treatment, and family support. Anti-depressants and anti-psychotics
are the most widely used medications for treating suicidal
tendencies. According to the World Health Organization (WHO), over
800,000 people die due to suicide annually. Development of an
effective anti-suicidal drug could be a major breakthrough in
reducing the death toll. Currently, non-profit organizations such as
Stop Suicide, Stop Youth Suicide, and American Foundation for Suicide
Prevention are providing moral and social support to people with
reported suicidal thoughts. This however, is ineffective until the
organization is alerted of the person at risk for suicide.
Request
For Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/10
Market
Dynamics
Off-label
use of these drugs for suicidal ideation has been a practice for
years, as there are no approved anti-suicide specific drug yet.
However, the dynamics is expected to change in the following few
years with the launch of first oral therapeutic drug for acute
suicidal ideation. This would disrupt the use of antidepressants and
anti-psychotic drugs for the treatment of suicidal tendencies.
Suicidal incidences are high in low and middle income countries
according to the WHO 2016 statistics. Although the incidence in Asia,
East Africa, and Eastern European region is high, these regions lag
in terms of availability of affordable medications and healthcare
facilities. Therefore developed economies of North America and
Western Europe are key target regions for manufacturers in the near
future. Rampant economic growth and projected strengthening of the
healthcare infrastructure in emerging economies in towards the first
half of the following decade is projected to shift the focus of these
companies towards highly populous regions of India and China in the
long run.
Market
Taxonomy
This
report segments the global anti-suicide
drugs market on the basis of chemistry type, and
geography. On the basis of chemistry type, the market is categorized
into anti-depressants and anti-anxiety drugs, anti-psychotic drugs,
NMDA antagonist and antibiotic analogs. For comprehensive
understanding of market dynamics, the global anti-suicide devices
market is analyzed across key geographical regions namely North
America, Europe, Asia Pacific, Latin America, Africa, and Middle
East. Each of these regions is analyzed on basis of market findings
across major countries in these regions for a macro-level
understanding of the market.
Anti-Suicide
Drugs Market to be on High Growth Trajectory Post Launch of
Anti-Suicidal Drug
NeuroRx
Pharma has developed a novel anti-suicidal product Cyclurad
(D-cycloserine and Lurasidone) which is indicated for Acute Suicidal
Ideation/Behavior (ASIB) in Bipolar Depression. The estimated
commercialization of the drug post-2020 is expected to be a major
breakthrough innovation for the anti-suicide drugs market. Moreover,
introduction of other such novel drugs for suicide would augment the
anti-suicide market growth. People with major depressive disorder and
risk for suicide would greatly benefit from such novel drug
therapies.
Anti-Suicide
Drugs Market to Gain Initial Traction in Developed Economies
Major
players operating in the global anti-suicide drugs market include
Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc,
GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx,
Inc., and Johnson & Johnson. High healthcare expenditure in
developed economies of North America and Europe is responsible for a
higher market size of anti-suicidal drugs in these regions. Moreover,
developed regions offer better healthcare infrastructure and are
usually early adopters of new therapies. The anti-suicide drugs
market in North America and Europe is expected to gain significant
traction during the latter half of the forecast period, with the
launch of anti-suicidal drug. Increasing healthcare expenditure in
emerging economies and high prevalence of suicides in these regions
is expected to bring about a paradigm shift in the market. Companies
are expected to focus on capitalizing on lucrative opportunities in
these regions at the turn of the following decade. This would ensure
sustained growth for the market in the foreseeable future.
Detailed
Segmentation:
Global
Anti-Suicide Drugs Market, By Chemistry Type:
•
Anti-Depressants and Anti-Anxiety Drugs
•
Anti-Psychotic Drugs
•
NMDA Antagonist
•
Antibiotic Analog
Global
Anti-Suicide Drugs Market, By Geography:
•
North America
•
Europe
•
Asia-Pacific
•
Latin America
•
Middle East
•
Africa
Grab
Your Report at an Impressive Discount @
https://www.coherentmarketinsights.com/insight/request-discount/10
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment